MSN: 'Human beings now have hope': UC doctor running Moderna trial says a big blow struck against coronavirus
Preliminary analysis shows vaccine has 95% efficacy
The preliminary analysis on the Moderna COVID-19 vaccine shows 94.5% efficacy, which is consistent with recent early results on the Pfizer vaccine. Carl Fichtenbaum, MD, of the UC Division of Infectious Diseases is a co-investigator of the trial on the Moderna vaccine being conducted at UC.
Carl Fichtenbaum, MD, of the UC Division of Infectious Diseases. Photo/Colleen Kelley/UC Creative + Brand
In a story published on MSN and Cincinnati.com, Fichtenbaum said “This is the beginning of the end because human beings now have hope.”
The Moderna vaccine candidate requires two injections 28 days apart. The Pfizer drug is delivered in two shots 21 days apart.
The two vaccines are similar in technology, using a fragment of the virus’ genetic code to go after the spiky proteins on the surface of the coronavirus. Without the crown of spikes, the virus can’t bind, and the body develops the ability to recognize the virus and fight it off.
The Pfizer candidate requires super-cold storage, which many providers do not have. Fichtenbaum said Monday that the advantage of the Moderna candidate is that it keeps at -4, “and most hospitals in the United States have freezers that have the capacity of holding at that temperature.”
The drug also is stable, Fichtenbaum said, “and could be given in a church parking lot over a vaccination day without losing any efficacy. We have reason to be incredibly hopeful.”
Fichtenbaum was also interviewed on this topic by the Cincinnati Business Courier, WLWT-TV and 700 WLW radio. Margaret Powers-Fletcher, co-investigator with Fichtenbaum on the Moderna vaccine trial at UC, was interviewed by Spectrum News.
Lead image/Colleen Kelley/UC Creative + Brand
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.